glp·helper
glphelper.com/wegovy/arizona/tempe
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® providers &
prescriptions in Tempe, AZ

Verified Wegovy providers in Tempe, AZ. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Wegovy weight loss →trial-anchored estimate
city providers
25
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Arizona
25 of 25 shown

Find an Wegovy provider in Arizona.

Every entry is checked against the NPI registry and the Arizona medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Arizona city · /wegovy/arizona/{city}
§ 03Getting Wegovy in Arizona
25 providers · 8 metros

How a prescription works in Arizona.

You don’t have to leave Arizona to start. Because semaglutide isn't a controlled substance, a Arizona-licensed prescriber can evaluate you by telehealth and send the script to a pharmacy near you, or you can see one of the 25 local providers below in person. What you pay depends on your plan, not your zip code.

Telehealth
Available in Arizona
Wegovy (semaglutide) is a GLP-1, not a controlled substance, so a Arizona-licensed clinician can assess you and prescribe over video, with no federal in-person-visit requirement.
Who can prescribe
AZ-licensed clinicians
Any physician, nurse practitioner, or PA licensed in Arizona can prescribe Wegovy. The 25 providers below are checked against the NPI registry and the Arizona board.
Medicaid (weight loss)
Diabetes only
As of April 2026, Arizona Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Arizona’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

At a glanceNDC 0169-4525
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon. Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Tempe

Tempe, Arizona has a population of 180,587 people. The adult obesity rate in Tempe is an age-adjusted estimate of 29.7%, 3.6 percentage points below the Arizona state rate of 33.3%. Diagnosed diabetes reaches 9.1% of adults in Tempe. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 18.1% of adults in Tempe.

of Tempe adults have obesity
29.7%
diagnosed diabetes
9.1%
no regular physical activity
18.1%

Age-adjusted estimates for Tempe, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossdo oral GLP-1 pills work
§ 05Support around Wegovy in Tempe
6 dietitians

The prescription is one part. Here is the rest, in Tempe.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Tempe, AZ, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Kylie Aaron, RDN, IBCLC
RD
Registered dietitian
2046 E Minton Dr
Call 480-415-2084NPI 1962109124
Breta Alstrom, RD
RD
Registered dietitian
701 W Rio Salado Pkwy Apt 1017
Call 620-491-3249NPI 1003388430
Jennifer Anthony, RD
RD
Registered dietitian
2900 E Detroit St
Call 480-748-7328NPI 1710713060
Sasha Bates, RD
RD
Registered dietitian
379 W Palomino Dr
Call 480-399-2275NPI 1982484366
Leah Beaird, MS, RD
RD
Registered dietitian · Renal
2141 E Warner Rd
Call 480-969-8714NPI 1346277688
Natalie Claassen, MS, RD
RD
Registered dietitian
1840 E Broadway Rd
Call 602-243-7277NPI 1144068099

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Selange Giannetto
NUTRITIONIST
Nutritionist
5626 S Marine Dr
Call 630-715-5838NPI 1013665744
Christine Hayes, B.S., R.N
NUTRITIONIST
Nutritionist · Education
1920 E Baseline Rd
Call 480-345-5000NPI 1982895389
John Kinsey
NUTRITIONIST
Nutritionist
1010 W Riviera Cir
Call 520-229-7329NPI 1235933524
Jennifer Ortlepp, MS,
NUTRITIONIST
Nutritionist
4404 E Pueblo Ave
Call 928-813-5448NPI 1700543469
Kelly Teal
NUTRITIONIST
Nutritionist
2066 E Ellis Dr
Call 520-709-1211NPI 1407744683
Christopher Yedlicka
NUTRITIONIST
Nutritionist
8400 S Kyrene Rd Ste 103
Call 602-698-7111NPI 1669056727
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Wegovy weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses; usually transient and dose-dependent
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$1,300 to $1,500
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $400
per month copay
Varies by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)
Typically denied
Most plans exclude weight-loss medications from formulary
Medicare Part D
Not covered
Statutory exclusion of weight-loss drugs in original Medicare[5]
Manufacturer savings card
as low as $0
per month for 12 mo
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Wegovy providers in Arizona

NPI-verified Wegovy (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Wegovy in other states

Find NPI-verified Wegovy (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Wegovy in Arizona

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]